首页|粤港澳大湾区药品监管规则分析

粤港澳大湾区药品监管规则分析

扫码查看
目的 为粤港澳大湾区药品监管规则的衔接提供参考。方法 运用政策分析法,对内地、香港、澳门地区的进口药品上市注册和上市后监管要素进行对比,分析异同点,探索在"一国两制"、3种法治并行的特殊区域内,确保药品质量安全的前提下,如何通过协同认可、规则衔接最终达到顺利通关和"要素流通"的目的。结果与结论 三地现有的药品监管制度是药品质量保障的坚实后盾。尽管制度存在差异,但通过挖掘内在联系,理清本质与表象的关系,通过协同认可的途径可实现区域化的制度接轨,从而解决制度执行中遇到的问题。
Drug Regulatory Rules in the Guangdong-Hong Kong-Macao Greater Bay Area
Objective To provide a reference for the connection of drug regulatory rules in the Guangdong-Hong Kong-Macao Greater Bay Area(GBA).Methods The registration and post-market drug regulatory elements of imported drugs in mainland China,Hong Kong,and Macau were compared by the policy analysis method,and the similarities and differences were analyzed to explore how to achieve smooth customs clearance and"element circulation"through mutual recognition and rule connection,while ensuring drug quality and safety in the special region with"One Country,Two Systems"and three parallel legal systems.Results and Conclusion The drug regulatory system in the three regions is a solid support for drug quality assurance.Although there are some institutional differences,regional institutional integration can be achieved by exploring internal connections,clarifying the relationship between essence and appearance,and through mutual recognition,thereby solving the problems encountered in institutional implementation.

Guangdong-Hong Kong-Macao Greater Bay Areadrug import filingmutual recognitiondrug administration

李立婕、张屿峰、何燕

展开 >

广东省广州市药品检验所,广东广州 510160

广东省广州市市场监督管理局,广东广州 510620

粤港澳大湾区 药品进口备案 协同认可 药品监管

2024

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
年,卷(期):2024.33(17)